Bactiguard aims to expand its licensing business to new therapeutic areas and Vigilenz’ ambition is to enhance its existing product range by introducing anti-infective properties. Therefore, the companies have signed a license agreement for Bactiguard coated orthopaedic trauma implant sets, covering the Asean markets (Malaysia, Indonesia, Thailand, Philippines, Singapore, Brunei, Vietnam, Myanmar, Cambodia & Laos).

“We are very excited about the partnership with Vigilenz as it expands our licensing business to orthopaedic implants that will permanently remain in the patient’s body. This new application will benefit from both the anti-infective and tissue friendly properties of the Bactiguard coating”, says Christian Kinch, CEO Bactiguard.

“By applying the Bactiguard coating to our surgical implants, we can prevent hospital acquired infections and reduce the suffering for patients who are often traumatized by accidents. I also see other potential future applications that would benefit greatly from the Bactiguard coating”, says S. Choudhury, CEO Vigilenz

The implants will initially be coated by Bactiguard. Vigilenz will be responsible for the CE certification process and for conducting clinical trials. As soon as the coated implants have been launched, Bactiguard will start receiving royalties.

Several years ago, Bactiguard entered a strategic partnership and licensing agreement with CR Bard, Inc (Bard) in the US. Since then, more than 140 million Bactiguard coated Foley-catheters have been sold worldwide. Bactiguard’s strategy is to expand the licensing business by adding new agreements to the current successful agreement with Bard.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 11 November 2015, at 08.20.

För ytterligare information vänligen kontakta:
Cecilia Edström, Director of Sales & New business, mobile: 46 722 262 328